report by BlackRock
Results for ""
Sustainable Investing
Demonstrating a Commitment to Sustainable Investing
This piece is approved to use with clients.
It's vital for financial advisors to be able to understand which values are important to their clients. Paul Arnold, Portfolio Manager, and Dan Kemp, Chief Investment Officer, EMEA, discuss how advisors can better understand why ESG is important to a client–whether it’s the expression of one’s values or something else.
Client Experience
4 Ways to Enhance Your Practice with Behavioral Finance
Redefining Behavioral Finance
Sustainable Investing
ESG in 2021: Closing the Expectations Gap
This piece is approved to use with clients.
Antony Marsden, Head of Governance and Responsible Investment, explores key themes related to Environmental, Social and Governance (ESG) investing in 2021, including why a rethink on ratings is necessary to align expectations with reality.
Sustainable Investing
Global Sustainable Equity: News and Opportunities
This piece is approved to use with clients.
Reflecting on the last quarter of 2020 and looking ahead to the opportunities in the world of sustainability.
Advisor Value & Fees
The Value of a Financial Professional
This piece is approved to use with clients.
There have been many studies conducted about the benefits and costs of professional financial advice. Most of the research has focused on portfolio performance and return generation. But are investors who receive professional guidance also more likely to feel confident about making important financial decisions than those who go it alone?
Client Experience
Enhance Client Relationships with Tech
The end of the year is an ideal time to check in with clients to gauge their financial and emotional wellbeing. Especially in the current environment, your clients may want reassurance that they’ll be okay.
Sustainable Investing
ESG Viewpoint – COVID-19 and the pharmaceutical industry
This piece is approved to use with clients.
Public trust in the pharmaceutical industry has eroded. The pandemic provides drug-makers a chance to begin re-building their reputation – but only if they prioritise socially responsible practices.